$2.05
4.44% today
Nasdaq, Nov 20, 08:50 pm CET
ISIN
US45256X1037
Symbol
IBRX

ImmunityBio Inc Stock price

$2.14
-0.31 12.65% 1M
-0.66 23.57% 6M
-0.42 16.41% YTD
-3.21 60.00% 1Y
-3.02 58.53% 3Y
-6.36 74.82% 5Y
-13.40 86.23% 10Y
-32.50 93.82% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.04 1.90%
ISIN
US45256X1037
Symbol
IBRX
Industry

New AI Insights on ImmunityBio Inc Insights AI Insights on ImmunityBio Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$2.7b
Net debt
$561.8m
Cash
$257.8m
Shares outstanding
985.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
25.5 | 19.6
EV/Sales
32.3 | 24.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-127.7%
Return on Equity
84.6%
ROCE
-56.5%
ROIC
-102.3%
Debt/Equity
-1.6
Financials (TTM | estimate)
Revenue
$82.6m | $107.6m
EBITDA
$-258.7m | -
EBIT
$-260.7m | $-286.4m
Net Income
$-348.6m | $-517.4m
Free Cash Flow
$-324.8m
Growth (TTM | estimate)
Revenue
1,026.3% | 629.7%
EBITDA
27.8% | -
EBIT
27.6% | 16.8%
Net Income
40.7% | -25.1%
Free Cash Flow
25.2%
Margin (TTM | estimate)
Gross
99.6%
EBITDA
-313.4% | -
EBIT
-315.8%
Net
-422.3% | -480.7%
Free Cash Flow
-393.4%
More
EPS
$-0.4
FCF per Share
$-0.3
Short interest
22.3%
Employees
680
Rev per Employee
$20.0k
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

Buy
91%
Hold
9%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
83 83
1,026% 1,026%
100%
- Direct Costs 0.37 0.37
-
0%
82 82
-
100%
- Selling and Administrative Expenses 153 153
4% 4%
185%
- Research and Development Expense 188 188
8% 8%
228%
-259 -259
28% 28%
-313%
- Depreciation and Amortization 2 2
0% 0%
2%
EBIT (Operating Income) EBIT -261 -261
28% 28%
-316%
Net Profit -349 -349
41% 41%
-422%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Positive
The Motley Fool
one day ago
Bought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value This new position ranks as the fund's 2nd-largest holding, representing 4.4% of AUM
Positive
Seeking Alpha
one day ago
ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-Hodgkin lymphoma, and a new Phase II trial for long COVID. Despite bullish long-term outlook, near-term risks include ongoing losses, potential dilution, regulatory hurdles, and manufacturing depen...
Neutral
Business Wire
7 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical treatment conversations. Fewer than one in five patients surveyed (18%) report their healthcare providers (HCPs) discuss all available treatment options during ...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today